Last reviewed · How we verify
Rescue Medication: Olopatadine ophthalmic drops
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the eye.
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the eye. Used for Allergic conjunctivitis (itching and redness associated with allergic reactions).
At a glance
| Generic name | Rescue Medication: Olopatadine ophthalmic drops |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Selective H1-receptor antagonist and mast cell stabilizer |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Olopatadine works through dual action: it competitively antagonizes H1 histamine receptors on ocular tissues, preventing histamine-induced itching and inflammation, while also stabilizing mast cells to reduce the release of inflammatory mediators. This combination provides both rapid symptom relief and sustained prevention of allergic ocular symptoms.
Approved indications
- Allergic conjunctivitis (itching and redness associated with allergic reactions)
Common side effects
- Ocular irritation or discomfort
- Headache
- Transient eye stinging or burning
- Blurred vision
Key clinical trials
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) (PHASE3)
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: